Literature DB >> 6491522

In vitro effect of Triton WR-1339 on canine plasma high density lipoproteins.

K Yamamoto, R Byrne, C Edelstein, B Shen, A M Scanu.   

Abstract

We studied the effect in vitro of various concentrations of Triton WR-1339 on normolipidemic canine plasma and on the high density lipoproteins (HDL) isolated from this plasma by ultracentrifugation. As a preamble to this study, we established that Triton WR-1339 has a unimer molecular weight of 4,500, a micellar molecular weight of 180,000, and a critical micellar concentration (CMC) of 0.018 mM or 0.008 g/dl. Above its CMC, Triton WR-1339 in concentrations between 2 and 10 mg/ml induced concentration-dependent structural changes in HDL which were characterized by a progressive displacement of apoA-I from the HDL surface without loss of lipids. The addition of Triton WR-1339 to the HDL particles modified their electrophoresis mobility and caused an increase in size (95 +/- 5 A to 114 +/- 7 A). At the extreme Triton WR-1339 concentrations utilized in these studies (10 mg/ml) disruption of the HDL particles occurred; at this stage, the original, relatively homogeneous, spherical HDL particles were replaced by a heterogeneous population ranging in size between 50 and 250 A, representing complexes of Triton WR-1339 with lipids essentially free of apoA-I which could be sedimented by ultracentrifugation. The effects of Triton WR-1339 on whole plasma or isolated HDL were comparable. These studies indicate that Triton WR-1339 in vitro alters HDL in a concentration-dependent manner and that these changes vary from a displacement of apoA-I from the HDL surface to a state where all lipids are solubilized into the Triton WR-1339 micellar phase and are driven away from the protein moiety.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6491522

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  3 in total

1.  Topical ophthalmic NSAIDs: a discussion with focus on nepafenac ophthalmic suspension.

Authors:  Bruce I Gaynes; Anne Onyekwuluje
Journal:  Clin Ophthalmol       Date:  2008-06

2.  The Long Term Kinetic of Plasma Lipids and Lipoproteins in Tyloxapol Injected Rats.

Authors:  Mehdi Rasouli; Hanieh Tahmouri; Mahboobeh Mosavi-Mehr
Journal:  J Clin Diagn Res       Date:  2016-06-01

3.  Synthesis and anti-hyperlipidemic evaluation of N‑(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats.

Authors:  Ghassan Shattat; Rania Al-Qirim; Yusuf Al-Hiari; Ghassan Abu Sheikha; Tariq Al-Qirim; Waseem El-Huneidi; Moyad Shahwan
Journal:  Molecules       Date:  2010-08-26       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.